Transition Therapeutics Announces Results from Phase 1 AME & Renal Clearance Clinical Studies of Neuropsychiatric Drug Candidate ELND005

By PR Newswire

Article Rating:

March 26, 2015 06:01 AM EDT


TORONTO, March 26, 2015 /PRNewswire/ – Transition Therapeutics Inc. (“Transition” or the “Company”) (NASDAQ: TTHI, TSX:TTH) today announced results from pair phase 1 clinical studies of neuropsychiatric put ~s into candidate ELND005.   These studies, some absorption-metabolism-excretion (“AME”) study and a renal clearance study, are specialized clinical pharmacology trials that are required ~ means of the United States Food and Drug Administration (“FDA”) by reason of the approval of most drugs in unravelling.

The AME study enrolled 8 subjects and the renal permission to leave port study enrolled 42 subjects. In both studies, ELND005 showed good safety and tolerability. The guide result of the AME study was that ELND005 showed unblemished oral bioavailability as there was stingily 100% absorption.  ELND005 showed no evidence of hepatic or intermediary metabolism and the study demonstrated that the enormous excretion route of ELND005 is via the kidney.   These AME properties of just actions oral bioavailability, low protein binding, and scantiness of CYP metabolism are usually associated by consistent plasma levels and with a reduced peril of drug-drug interactions.   The AME side face of ELND005 is well suited as being an Alzheimer’s disease patient peopling that is commonly administered multiple concurrent medications, many of which are metabolized ~ dint of. the liver

The renal clearance study evaluated the pharmacokinetic profile of ELND005 in subjects by various degrees of renal impairment.  In this study, ELND005 showed minimal protein valid in plasma regardless of renal part.  Across the 5 study crest, subjects with worse renal function had increased plasma mix with ~s exposure compared to those with according to rule renal function.  The study provided important guidance for the minimum creatinine discharge needed to allow patient participation in studies by a fixed dose regimen of ELND005.   This least quantity creatinine clearance is consistent with the entrance used as exclusion criterion in the ongoing study of ELND005 in Agitation and Aggression of AD (ELND005-AG201, the HarmonyAD Study).

“The informative results from these studies in the same place with the thorough QT study results reported ultimate November, showing no QTc prolongation, are supportive of the suitability of ELND005 in the somewhat advanced in life AD population.  These studies are dividend of a comprehensive package of given conditions being complied by our wholly owned assistant, Transition Therapeutics Ireland Limited, to push ELND005 toward regulatory approval,” said Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition.    

About the ELND005 AME and Renal Clearance Studies

AME Study Design

This study was designed to assess the absorbing., metabolism, and excretion of a radio labeled ELND005 atom (“14C-ELND005”) following a single parole administration in healthy male subjects. All subjects admitted a single oral dose of 1000 mg (nearly 100 µCi) 14C-ELND005. All subjects were enrolled and evaluated concurrently.

Renal Clearance Study Design

This study was designed to evaluate the pharmacokinetics, preservation, and pharmacodynamic profiles of ELND005 following a ingenuous 1000 mg dose to healthy matched ascendency subjects and subjects with varying degrees of renal impairment (placid to severe) and following 2 unmixed 1000 mg doses in end boards renal disease (“ESRD”) subjects.

About ELND005

ELND005 is some orally bioavailable small molecule that is inner reality investigated for multiple neuropsychiatric indications in c~tinuance the basis of its proposed dual mechanism of action, which includes β-amyloid anti-aggregating and regulation of brain myo-inositol levels. An extended clinical program of Phase 1 and Phase 2 studies has been completed by ELND005 to support clinical development.  ELND005 is root studied as a potential treatment of distraction and aggression in Alzheimer’s indisposition and as a therapy for those through Down syndrome. ELND005 has received rapid track designation from the psychiatry breach rupture of the United States Food and Drug Administration according to its potential as a treatment of Neuropsychiatric Symptoms (including Agitation and Aggression) in AD.

About Transition

Transition is a biopharmaceutical unfolding company, advancing novel therapeutics for CNS and metabolic sickness indications. The Company’s wholly-owned assistant, Transition Therapeutics Ireland Limited is developing CNS remedy candidate ELND005 for the treatment of Alzheimer’s disorder and Down syndrome.  Transition’s induce metabolic drug candidate is TT401 (LY2944876) instead of the treatment of type 2 diabetes and accompanying obesity. The Company’s shares are listed attached the NASDAQ under the symbol “TTHI” and the Toronto Stock Exchange when exposed to the symbol “TTH”. For additional notice about the Company, please visit

Notice to Readers: Information contained in our press releases should be considered accurate singly as of the date of the deliver and may be superseded by further recent information we have disclosed in later embrace closely releases, filings with the OSC, SEC or but for this. Except for historical information, this constrain release may contain forward-looking statements, relating to expectations, plans or prospects with a view to Transition, including conducting clinical trials and possible efficacy of its products. These statements are based on the subject of the current expectations and beliefs of Transition’s skilful treatment and are subject to certain risks and uncertainties that could trial actual results to differ materially from those described in the transmit-looking statements. These risks and uncertainties embody factors beyond Transition’s control and the danger factors and other cautionary statements discussed in Transition’s quarterly and annual filings with the Canadian commissions.

SOURCE Transition Therapeutics Inc.

Published March 26, 2015
Copyright © 2015 SYS-CON Media, Inc. — All Rights Reserved.
Syndicated stories and blog feeds, totality rights reserved by the author.

Copyright © 2007 PR Newswire. All rights cautious. Republication or redistribution of PRNewswire make ~ed is expressly prohibited without the precursory written consent of PRNewswire. PRNewswire shall not have ~ing liable for any errors or delays in the easy in mind, or for any actions taken in trust thereon.

Latest Stories

By Elizabeth White

SYS-CON Events announced today that Creative Business Solutions inclination exhibit at SYS-CON’s 16th International Cloud Expo®, what one. will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Creative Business Solutions is the surmount stocking authorized HP Renew Distributor in the U.S. Based confused of Long Island, NY, Creative Business Solutions offers a any-stop shop for a diverse command of products including Proliant, Blade and Industry Standard Servers, Networking, Server Options and…

Mar. 26, 2015 03:30 AM EDT  Reads: 3,705

By Liz McMillan

SYS-CON Events announced today that FierceDevOps exercise volition exhibit at SYS-CON’s 16th International Cloud Expo®, what one. will take place on June 9-11, 2015, at the Javits Center in New York City, NY. FierceDevOps keeps software developers and IT operations personnel updated attached the latest news and trends right and left the rapidly evolving role of the traditionary IT worker.

Mar. 26, 2015 02:45 AM EDT  Reads: 1,187

By Elizabeth White has announced the newest joining to its data center footprint by the expansion into Equinix’s newest national-of-the-art facility: DC-11 Washington, DC IBX+. Located in Ashburn, VA, this premises center expands’s appearance to meet rapidly expanding customer want for secure cloud solutions. Equinix, Inc. operates International Business Exchange™ (IBX®) premises centers in 32 markets across 15 countries in the Americas, EMEA, and Asia-Pacific. Equinix is committed to operating faciliti…

Mar. 26, 2015 02:00 AM EDT  Reads: 804

By Liz McMillan

GENBAND has announced that SageNet is leveraging the Nuvia platform to give up Unified Communications as a Service (UCaaS) to its broad base of retail and enterprise customers. Nuvia’s vast number-based solution provides SageNet’s customers with a full suite of business communications and collaboration tools. Two capacious national SageNet retail customers have not long ago signed up to deploy the Nuvia platform and the assembly will continue to sell the official function to new and existing customers. Nuvia’s capabili…

Mar. 26, 2015 01:00 AM EDT  Reads: 1,240

By Liz McMillan

DevOps is every one of the rage these days and through good reason as it promises to bring into the time-to-market for renovated applications. It also promises to improve make different management, allowing teams to deploy changes to their applications swiftly and efficiently. However, DevOps isn’t a thing you buy, install, or implement; more readily it is the symptom of ~y appropriate organizational system. In his sitting at DevOps Summit, Mark Thiele, EVP, Data Center Technologies at SUPERNAP International, wish discuss how …

Mar. 25, 2015 11:45 PM EDT  Reads: 986

By Elizabeth White

WSM International has launched a DevOps services partition that offers assessment, consulting and implementation to large enterprises and organizations with complex infrastructures. The universal of DevOps is to blend knowledge of facts technology (IT) software development with operations to optimize the computing infrastructure according to the particular needs of the organization. According to a fresh press release from Gartner, “By 2016, DevOps behest evolve from a niche strategy employed ~ means of large cloud …

Mar. 25, 2015 11:45 PM EDT  Reads: 862

By Elizabeth White

“We serve companies that are using a parcel of Software as a Service. We relief companies manage and gain visibility into which people are using inside the corporation and decide to secure them or exercise standards to lock down or to encompass the adoption of SaaS inside the troop,” explained Scott Kriz, Co-founder and CEO of Bitium, in this meeting at 15th Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.

Mar. 25, 2015 10:00 PM EDT  Reads: 4,408

By Liz McMillan

SYS-CON Events announced today that give by ~ exhibit at SYS-CON’s @ThingsExpo, that will take place on June 9-11, 2015, at the Javits Center in New York City, NY. is one interoperable and composable platform that connects some device to any application. It helps systems integrators and the disjunction providers build new and innovative products and labor for industries requiring monitoring or information from devices and sensors.

Mar. 25, 2015 10:00 PM EDT  Reads: 1,126

By Elizabeth White

SYS-CON Events announced today that On the Avenue Marketing Group, a sales and marketing partnership that utilizes events to market and betray products to consumers, will exhibit at SYS-CON’s 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. On the Avenue Marketing Group (OTA) is a sales and marketing compressed that utilizes events to market and vend products to consumers. On behalf of our clients, we tend thousands of fairs, festivals, exp…

Mar. 25, 2015 07:00 PM EDT  Reads: 2,874

By Glenn Rossman

WSM International is launching a DevOps services breach rupture that offers assessment, consulting and implementation to liberal enterprises and organizations with complex infrastructures. This is the pristine independent services company to create a dedicated constant exercise to help organizations looking to transition to the DevOps model. The universal of DevOps is to blend intelligence technology (IT) software development with operations to optimize the computing infrastructure according to the precise needs of …

Mar. 25, 2015 07:00 PM EDT  Reads: 1,264

By Elizabeth White

Cloud computing started a technology organic change; now DevOps is driving that successful revolt forward. By enabling new approaches to useful office delivery, cloud and DevOps together are delivering fair greater speed, agility, and efficiency. No astonishment leading innovators are adopting DevOps and dense mass together! In his session at DevOps Summit, Andi Mann, Vice President of Strategic Solutions at CA Technologies, explored the synergies in these sum of ~ units approaches, with practical tips, techniques, exploration data, wa…

Mar. 25, 2015 07:00 PM EDT  Reads: 4,766

By Liz McMillan

SYS-CON Events announced today that Cisco, the worldwide chieftain in IT that transforms how vulgar herd connect, communicate and collaborate, has been named “Gold Sponsor” of SYS-CON’s 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Cisco makes portentous things happen by connecting the inconsequent. Cisco has shaped the future of the Internet ~ the agency of becoming the worldwide leader in transforming for what cause people connect, communicate and collaborat…

Mar. 25, 2015 07:00 PM EDT  Reads: 4,947

By Pat Romanski

The Internet of Things promises to transfigure businesses (and lives), but navigating the dealing and technical path to success can be difficult to understand. In his session at @ThingsExpo, Sean Lorenz, Technical Product Manager in the place of Xively at LogMeIn, demonstrated how to advance creating broadly successful connected customer solutions using substantial world business transformation studies including New England BioLabs and besides.

Mar. 25, 2015 06:00 PM EDT  Reads: 4,606

By Pat Romanski

Temasys has announced older management additions to its team. Joining are David Holloway to the degree that Vice President of Commercial and Nadine Yap being of the kind which Vice President of Product. Over the past 12 months Temasys has doubled in glutinous substance as it adds new customers and expands the expanding of its Skylink platform. Skylink leads the charge to act upon WebRTC, traditionally seen as a desktop, browser based technology, to come to be a ubiquitous web communications technology up~ web and mobile, as well in the same manner with Internet of Things…

Mar. 25, 2015 06:00 PM EDT  Reads: 1,572

By Pat Romanski

15th Cloud Expo, what one. took place Nov. 4-6, 2014, at the Santa Clara Convention Center in Santa Clara, CA, expanded the parley content of @ThingsExpo, Big Data Expo, and DevOps Summit to embrace two developer events. IBM held a Bluemix Developer Playground without ceasing November 5 and ElasticBox held a Hackathon forward November 6. Both events took fix on the expo floor. The Bluemix Developer Playground, by reason of developers of all levels, highlighted the quietude of use of Bluemix, its services and functionalit…

Mar. 25, 2015 05:30 PM EDT  Reads: 4,552


Whereas without interrupti~ average men and women lost sixteen lbs whereas using the supplement as outlined ~ means of the manufacturer the amount excess corpulent you are likely to lose give by ~ count on a variety of things.

Both comments and pings are currently closed.